Shanghai Novarock Biopharmaceutical

Novarock Biopharmaceutical is a clinical-stage biopharmaceutical company specializing in the discovery and development of innovative antibody-based therapies for oncology and autoimmune diseases. Founded in 2018 and headquartered in Shanghai with a significant R&D presence in the United States, the company utilizes its proprietary Nova-Body platform to engineer highly differentiated biologics, including monoclonal and bispecific antibodies. In 2021, Novarock was acquired by CSPC Pharmaceutical Group, a move that integrated its advanced biologics pipeline into one of China's largest pharma portfolios. The company's lead assets target high-impact pathways such as IL-23 for chronic inflammatory conditions and Claudin 18.2 for gastrointestinal malignancies. Novarock continues to operate as a key innovation engine for its parent company, advancing multiple programs through global clinical trials.